Boryung Pharmaceutical
CompanySouth Korea
Boryung Pharmaceutical Co., Ltd develops 6 assets, the furthest approved (atorvastatin in angina). Mostly small molecule acting on lipid and ceramide metabolism, HMGCR and SLC5A2; based in South Korea.
- Assets
- 6
- Furthest
- Approved
- Trials
- 21
- Signals
- 2
Pipeline
6HMG-CoA reductase inhibitor that suppresses cholesterol biosynthesis and lowers plasma LDL levels
ApprovedSmall moleculeAMPK signallingLipid and ceramide metabolismanginacoronary heart disease
Inhibits SGLT2 (SLC5A2) to block renal glucose reabsorption.
ApprovedSmall moleculeLipid and ceramide metabolismNutrient sensingcardiovascular deathchronic kidney disease
Inhibits ATP citrate lyase to reduce cholesterol biosynthesis
ApprovedSmall moleculeAMPK signallingLipid and ceramide metabolismheterozygous familial hypercholesterolemiahomozygous familial hypercholesterolemia
3 more assets
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms9
- Trials26
- Signals13
- Similar companies6
Updated 7 Oct 2026 · 308 sources